AUPH - Aurinia Pharmaceuticals Inc.

16.04
-0.330   -2.057%

Share volume: 858,259
Last Updated: 04-28-2026
Pharmaceutical Products/Pharmaceutical Preparations: -0.12%

PREVIOUS CLOSE
CHG
CHG%
$16.37
-0.33
-0.02%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Overview Charts Financials Fundamental analysis Historical prices Events Documents Notes Dividends
Fundamental analysis
65%
Profitability 65%
Dept financing 25%
Liquidity 75%
Performance 74%
Company vs Stock growth
vs
+ Add row to compare
Performance
5 Days
0.38%
1 Month
14.74%
3 Months
9.49%
6 Months
31.26%
1 Year
97.54%
2 Year
220.16%
Key data
Stock price
$16.04
P/E Ratio 
7.32
DAY RANGE
$16.01 - $16.62
EPS 
$2.14
52 WEEK RANGE
$7.28 - $16.88
52 WEEK CHANGE
$94.66
MARKET CAP 
2.103 B
YIELD 
N/A
SHARES OUTSTANDING 
132.971 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
05-01-2025
BETA 
0.87
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$1,061,323
AVERAGE 30 VOLUME 
$1,087,320
Company detail
CEO: Peter S. Greenleaf
Region: US
Website: auriniapharma.com
Employees: 300
IPO year: 2008
Issue type: Common Stock
Market: XNAS
Industry: Pharmaceutical Products/Pharmaceutical Preparations
Sector: Manufacturing

Aurinia Pharmaceuticals Inc. focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States and internationally. The company offers LUPKYNIS for the treatment of adult patients with active lupus nephritis.

Recent news